The stratification of ANA ≥ 1:160 positive MDS according to the 2016 WHO classification and IPSS-R score did not show a statistically significant association between ANA positivity and a specific MDS subgroup, although patients with intermediate risk showed the higher frequency of ANA positivity. This evidence concerns the gene BTG3 and myelodysplastic syndrome.